Trial Profile
Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2021
Price :
$35
*
At a glance
- Drugs Fluocinonide (Primary) ; Imiquimod (Primary)
- Indications Mycosis fungoides
- Focus Therapeutic Use
- 23 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Oct 2019 Planned End Date changed from 2 Aug 2019 to 1 Apr 2023.
- 08 Oct 2019 Planned primary completion date changed from 2 Aug 2019 to 1 Apr 2022.